Mithra Pharmaceuticals

Mithra Pharmaceuticals SA. Mithra Pharmaceuticals SA is a Belgium-based company active in the pharmaceutical industry. The Company is dedicated to provide products and services for the fertility, contraception and menopause of women. It has a number of patent families regarding Estetrol (E4), a natural estrogen produced by the human foetus, which enables the investigation of fertility and contraception products. Mithra is focused on the development of two late-stage E4-based products: Estelle, a 5th generation oral contraceptive, and Donesta, a hormone therapy for Vasomotor Symptoms in menopause. Mithra develops a contraceptive vaginal ring called Myring and Zoreline, a biodegradable subcutaneous implant for hormone dependant cancer.
  • TickerMITRA
  • ISINBE0974283153
  • ExchangeEuronext Brussels
  • SectorPharmaceuticals & Biotechnology
  • CountryBelgium
Guy Sips ...
  • Sandra Cauwenberghs

Morning Note: FLOB BB, MITRA BB

Floridienne: Withstanding negative consequences of Covid-19 Mithra: Estetrol is joining the SARS drug search

Bart Cuypers ...
  • Jason Kalamboussis
  • Joachim Vansanten
  • Lenny Van Steenhuyse
  • Michiel Declercq
  • Ruben Devos
  • Sandra Cauwenberghs
  • Wido Jongman

Morning Note: ACKB BB, AED BB, ASRNL NA, CFEB BB, ELI BB, GIMB BB, HAL NA, HOMI BB, IVA FP, MITRA BB, ROU BB, TWEKA NA

Ackermans: 1Q Trading update Aedifica: 3Q19-20 trading update ASR: Weak 1Q, profit warning. Solid Solvency though. CFE: Soft DEME revenue and strongly impacted FY20 Elia Group: Steady as she goes Gimv: FY19/20 Results imply a large premium Hal Trust: 1Q20 Update Home Invest Belgium: 1Q20 Results show signs of improvement Inventiva: € 10m government-backed loan secured Mithra: Estelle NDS filed in Canada. Potential launch mid-21. Roularta: Qualitative trading update TKH Group: Forward EPS lowered by 25-35%, new TP of € 45

Alan Vandenberghe ...
  • Guy Sips
  • Lenny Van Steenhuyse
  • Ruben Devos
  • Sandra Cauwenberghs
  • Wim Hoste

Morning Note: AGFB BB, BALTA BB, BPOST BB, DSM NA, GVNV NA, IVA FP, MITRA BB

Agfa: Completed sale of part of HealthCare’s IT business Balta: 1Q results still OK, coming quarters will be tougher bpost: Slightly better Q1 results, no dividend update yet DSM: Preview: resilience from Nutrition expected in 1Q GrandVision: Materially affected by COVID-19 Inventiva: NATIVE-trial baseline characteristics disclosed Mithra: Myring commercialization in Switzerland with Gynial

Alan Vandenberghe ...
  • Bart Cuypers
  • Guy Sips
  • Lenny Van Steenhuyse
  • Ruben Devos
  • Sandra Cauwenberghs
  • Thomas Couvreur

Morning Note: ADYEN NA, ARCAD NA, BOKA NA, CFEB BB, ECONB BB, ENX FP, MIKO BB, MITRA BB, SIOE BB

Adyen: Covid-19 is killing cash payments Arcadis: Weathering the storm well so far Boskalis: Oil my glut – adjustment investment case CFE: Oil my glut – adjustment investment case Econocom: 1Q20 trading update Euronext: Expansion into Nordics continues Miko: Huge difference of impact between the two branches Mithra: Capital Commitment secured for € 50m with LDA Sioen: 3.4% revs decline in 1Q20, 35% sales drop in Apr’20 Various: Oil my glut

MITHRA SA sees a downgrade to Slightly Negative on account of less fundamental stars

The independent financial analyst theScreener just lowered the general evaluation of MITHRA SA (BE), active in the Pharmaceuticals industry. As regards its fundamental valuation, the title now shows 2 out of 4 stars while market behaviour can be considered risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Slightly Negative. As of the analysis date April 21, 2020, the closing price was EUR 21.20 and its target price was estimated at EUR 15.23.

Mithra Pharmaceuticals: 1 director sold

A director at Mithra Pharmaceuticals sold 560,200 shares at 25.572EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The name...

Guy Sips ...
  • Sandra Cauwenberghs

Morning Note: FLOB BB, MITRA BB

Floridienne: Withstanding negative consequences of Covid-19 Mithra: Estetrol is joining the SARS drug search

Bart Cuypers ...
  • Jason Kalamboussis
  • Joachim Vansanten
  • Lenny Van Steenhuyse
  • Michiel Declercq
  • Ruben Devos
  • Sandra Cauwenberghs
  • Wido Jongman

Morning Note: ACKB BB, AED BB, ASRNL NA, CFEB BB, ELI BB, GIMB BB, HAL NA, HOMI BB, IVA FP, MITRA BB, ROU BB, TWEKA NA

Ackermans: 1Q Trading update Aedifica: 3Q19-20 trading update ASR: Weak 1Q, profit warning. Solid Solvency though. CFE: Soft DEME revenue and strongly impacted FY20 Elia Group: Steady as she goes Gimv: FY19/20 Results imply a large premium Hal Trust: 1Q20 Update Home Invest Belgium: 1Q20 Results show signs of improvement Inventiva: € 10m government-backed loan secured Mithra: Estelle NDS filed in Canada. Potential launch mid-21. Roularta: Qualitative trading update TKH Group: Forward EPS lowered by 25-35%, new TP of € 45

Alan Vandenberghe ...
  • Guy Sips
  • Lenny Van Steenhuyse
  • Ruben Devos
  • Sandra Cauwenberghs
  • Wim Hoste

Morning Note: AGFB BB, BALTA BB, BPOST BB, DSM NA, GVNV NA, IVA FP, MITRA BB

Agfa: Completed sale of part of HealthCare’s IT business Balta: 1Q results still OK, coming quarters will be tougher bpost: Slightly better Q1 results, no dividend update yet DSM: Preview: resilience from Nutrition expected in 1Q GrandVision: Materially affected by COVID-19 Inventiva: NATIVE-trial baseline characteristics disclosed Mithra: Myring commercialization in Switzerland with Gynial

Alan Vandenberghe ...
  • Bart Cuypers
  • Guy Sips
  • Lenny Van Steenhuyse
  • Ruben Devos
  • Sandra Cauwenberghs
  • Thomas Couvreur

Morning Note: ADYEN NA, ARCAD NA, BOKA NA, CFEB BB, ECONB BB, ENX FP, MIKO BB, MITRA BB, SIOE BB

Adyen: Covid-19 is killing cash payments Arcadis: Weathering the storm well so far Boskalis: Oil my glut – adjustment investment case CFE: Oil my glut – adjustment investment case Econocom: 1Q20 trading update Euronext: Expansion into Nordics continues Miko: Huge difference of impact between the two branches Mithra: Capital Commitment secured for € 50m with LDA Sioen: 3.4% revs decline in 1Q20, 35% sales drop in Apr’20 Various: Oil my glut

UOB
Stevanus Juanda

Mitra Adiperkasa (MAPI IJ) - 80%+ yoy Decline In 2020 Core Net Income, Similar To The Drop Seen During GFC Period

Our channel checks indicate a potentially significant decline in MAPI’s 2020 net income. Mall closures in Jakarta and other major cities have been observed in Indonesia. During the GFC period, we observed an 82% yoy decline in 2009 core earnings. We have incorporated a similar 80% decline to MAPI’s 2020F core earnings. Considering the ytd 45% decline in share price, we believe much of the bad news has been priced in. Maintain BUY with a lower target price of Rp770, or or 26% upside from current price levels.

MITHRA SA sees a downgrade to Slightly Negative on account of less fundamental stars

The independent financial analyst theScreener just lowered the general evaluation of MITHRA SA (BE), active in the Pharmaceuticals industry. As regards its fundamental valuation, the title now shows 2 out of 4 stars while market behaviour can be considered risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Slightly Negative. As of the analysis date April 21, 2020, the closing price was EUR 21.20 and its target price was estimated at EUR 15.23.

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch